Commonly used in clinical treatment of breast cancer trastuzumab (trastuzumab): Commodity Minghesaiting (herceptin), a humanized chimeric monoclonal antibody treatment of, mainly for the treatment of HER -2 (who EGFR -2 tyrosine kinase receptor) positive breast cancer in 1998, FDA approved for the treatment of metastatic breast cancer.
Clinical treatment of the drug alone 222 cases, there is over-expression of HER-2/neu gene in patients with advanced breast cancer rate was 15% 0 the median response duration 9.1 months, median survival of 13 months, median progression Time 3. Jan. O positive degree other HER -2 to + + + effective rate of 189 patients with hair, shows higher levels of HER -2 overexpression, trastuzumab clinical effect is better. The results also showed that trastuzumab can increase the HER-2 positive metastatic breast cancer patients quality of life and overall capacity. Phase III clinical trials, the combination of doxorubicin or paclitaxel and vinorelbine can significantly improve the outcome.
Commonly used in clinical breast cancer treatment rituximab (rituxan): trade name MabThera (mabthera), is a mouse constant regions with human variable region binding to the CD20 antigen-specific chimeric monoclonal antibody O is mainly used in non-Hodgkin lymphoma, breast cancer is also effective.
Commonly used in clinical treatment of breast cancer Lapatinib (lapatinib): In vitro tests show, Lapatinib combined with tamoxifen can inhibit the anti-estrogen resistance in breast cancer cell proliferation and estrogen dependent gene expression, clinical trials found that, for He Competition Ting-resistant breast cancer patients with Lapatinib is still valid.